The University of Chicago Header Logo

Connection

David Kim to Humans

Back to Details
This is a "connection" page, showing publications David Kim has written about Humans.
David Kim
Connection Strength
0.864
Humans
  1. Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions. Health Qual Life Outcomes. 2024 Sep 02; 22(1):72.
    View in: PubMed
    Score: 0.032
  2. An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau. Am J Manag Care. 2024 Aug; 30(8):348-350.
    View in: PubMed
    Score: 0.031
  3. Patient-Provider Communication and Access, Use, and Financial Burden of Care. Am J Prev Med. 2024 Nov; 67(5):740-745.
    View in: PubMed
    Score: 0.031
  4. The role of simulation modelling in public health policy evaluation. Lancet Public Health. 2024 Mar; 9(3):e150-e151.
    View in: PubMed
    Score: 0.030
  5. Development and Validation of the US Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) Model: Health Disparity and Economic Impact Model. Med Decis Making. 2023 Oct-Nov; 43(7-8):930-948.
    View in: PubMed
    Score: 0.030
  6. Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy. Pharmacoeconomics. 2023 09; 41(9):1151-1164.
    View in: PubMed
    Score: 0.029
  7. Developing Criteria for Health Economic Quality Evaluation Tool. Value Health. 2023 08; 26(8):1225-1234.
    View in: PubMed
    Score: 0.029
  8. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending. JAMA Netw Open. 2022 11 01; 5(11):e2243449.
    View in: PubMed
    Score: 0.028
  9. State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage Populations. Health Aff (Millwood). 2022 09; 41(9):1281-1290.
    View in: PubMed
    Score: 0.027
  10. Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage Population. Med Care. 2022 12 01; 60(12):888-894.
    View in: PubMed
    Score: 0.027
  11. A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. Value Health. 2022 08; 25(8):1298-1306.
    View in: PubMed
    Score: 0.027
  12. The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value Health. 2022 08; 25(8):1336-1343.
    View in: PubMed
    Score: 0.027
  13. How Does Cost-Effectiveness Analysis Inform Health Care Decisions? AMA J Ethics. 2021 08 01; 23(8):E639-647.
    View in: PubMed
    Score: 0.025
  14. Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence? Value Health. 2021 11; 24(11):1586-1591.
    View in: PubMed
    Score: 0.025
  15. An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 11; 36(11):3448-3455.
    View in: PubMed
    Score: 0.025
  16. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. Pharmacoeconomics. 2020 10; 38(10):1135-1145.
    View in: PubMed
    Score: 0.024
  17. Crisis into opportunity: can COVID-19 help set a path to improved health care efficiency? Am J Manag Care. 2020 09; 26(9):369-370.
    View in: PubMed
    Score: 0.024
  18. Growth and capacity for cost-effectiveness analysis in Africa. Health Econ. 2020 08; 29(8):945-954.
    View in: PubMed
    Score: 0.023
  19. Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences. Med Decis Making. 2020 04; 40(3):251-253.
    View in: PubMed
    Score: 0.023
  20. Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. Pharmacoeconomics. 2020 02; 38(2):171-179.
    View in: PubMed
    Score: 0.023
  21. Comparative Modeling to Inform Health Policy Decisions: A Step Forward. Ann Intern Med. 2019 12 03; 171(11):851-852.
    View in: PubMed
    Score: 0.023
  22. Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S. Am J Prev Med. 2019 11; 57(5):e143-e152.
    View in: PubMed
    Score: 0.022
  23. Leveraging Cumulative Network Meta-analysis and Value of Information Analysis to Understand the Evolving Value of Medical Research. Med Decis Making. 2019 02; 39(2):119-129.
    View in: PubMed
    Score: 0.021
  24. Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Health Aff (Millwood). 2019 01; 38(1):60-67.
    View in: PubMed
    Score: 0.021
  25. Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Med Care. 2018 07; 56(7):583-588.
    View in: PubMed
    Score: 0.021
  26. Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. Obes Surg. 2018 05; 28(5):1321-1328.
    View in: PubMed
    Score: 0.020
  27. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):615-623.
    View in: PubMed
    Score: 0.019
  28. New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. Med Decis Making. 2017 11; 37(8):930-941.
    View in: PubMed
    Score: 0.019
  29. Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis. Value Health. 2016 Jul-Aug; 19(5):602-13.
    View in: PubMed
    Score: 0.018
  30. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health. 2015; 10(3):296-317.
    View in: PubMed
    Score: 0.016
  31. Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. 2024 Oct 01; 130(19):3305-3310.
    View in: PubMed
    Score: 0.008
  32. Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study. J Am Heart Assoc. 2023 08; 12(15):e029215.
    View in: PubMed
    Score: 0.007
  33. What is the cost-effectiveness of menu calorie labelling on reducing obesity-associated cancer burdens? An economic evaluation of a federal policy intervention among 235 million adults in the USA. BMJ Open. 2023 04 18; 13(4):e063614.
    View in: PubMed
    Score: 0.007
  34. Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. N Engl J Med. 2023 Mar 16; 388(11):961-963.
    View in: PubMed
    Score: 0.007
  35. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022 07 12; 80(2):138-151.
    View in: PubMed
    Score: 0.007
  36. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine. 2021 11 05; 39(46):6727-6734.
    View in: PubMed
    Score: 0.006
  37. Cost-effectiveness Analysis of Nutrition Facts Added-Sugar Labeling and Obesity-Associated Cancer Rates in the US. JAMA Netw Open. 2021 04 01; 4(4):e217501.
    View in: PubMed
    Score: 0.006
  38. Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Med Decis Making. 2021 04; 41(3):366-372.
    View in: PubMed
    Score: 0.006
  39. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. Health Aff (Millwood). 2021 01; 40(1):53-61.
    View in: PubMed
    Score: 0.006
  40. Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. Prog Neuropsychopharmacol Biol Psychiatry. 2021 03 02; 106:110084.
    View in: PubMed
    Score: 0.006
  41. Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in China. Value Health. 2020 11; 23(11):1405-1408.
    View in: PubMed
    Score: 0.006
  42. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter? Int J Technol Assess Health Care. 2020 Apr; 36(2):96-103.
    View in: PubMed
    Score: 0.006
  43. Are low and middle-income countries prioritising high-value healthcare interventions? BMJ Glob Health. 2020; 5(2):e001850.
    View in: PubMed
    Score: 0.006
  44. Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ. 2020 01 28; 368:m141.
    View in: PubMed
    Score: 0.006
  45. Variation in US private health plans' coverage of orphan drugs. Am J Manag Care. 2019 10; 25(10):508-512.
    View in: PubMed
    Score: 0.006
  46. Future Directions for Cost-effectiveness Analyses in Health and Medicine. Med Decis Making. 2018 10; 38(7):767-777.
    View in: PubMed
    Score: 0.005
  47. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Med. 2018 09; 7(9):4251-4260.
    View in: PubMed
    Score: 0.005
  48. Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Aff (Millwood). 2018 07; 37(7):1041-1047.
    View in: PubMed
    Score: 0.005
  49. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018 07; 21(7):759-761.
    View in: PubMed
    Score: 0.005
  50. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013 Sep; 120(9):1835-42.
    View in: PubMed
    Score: 0.004
  51. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012 Apr; 130(4):497-505.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.